SIWV tetrapeptide and ROS-responsive prodrug conjugate for advanced glioblastoma therapy

Yoon Kyung Park, Paramesh Jangili, Soyu Zi, Rae Hyung Kang, Dokyoung Kim, Jong Seung Kim

Research output: Contribution to journalArticlepeer-review

Abstract

A new conjugate formulation, SIWV-PB-SN, based on glioblastoma (GBM)-homing SIWV tetrapeptide and an ROS-responsive prodrug is reported. SIWV-PB-SN selectively penetrates the GBM cells and releases anti-GBM drug (SN-38) via ROS-induced linker cleavage. This study presents a new insight for a more advanced therapeutic approach to overcoming GBM.

Original languageEnglish
Pages (from-to)10941-10944
Number of pages4
JournalChemical Communications
Volume58
Issue number78
DOIs
Publication statusPublished - 2022 Sep 9

ASJC Scopus subject areas

  • Catalysis
  • Electronic, Optical and Magnetic Materials
  • Ceramics and Composites
  • Chemistry(all)
  • Surfaces, Coatings and Films
  • Metals and Alloys
  • Materials Chemistry

Fingerprint

Dive into the research topics of 'SIWV tetrapeptide and ROS-responsive prodrug conjugate for advanced glioblastoma therapy'. Together they form a unique fingerprint.

Cite this